Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Results vary from person to person depending on metabolism, lifestyle habits, and adherence to treatment recommendations
Retatrutide could trigger: price adjustments for existing GLP-1 drugs innovation of new multi-agonist peptides expansion of obesity-drug insurance coverage more investment into metabolic-disease research Impact on UK Healthcare If retatrutide delivers the same results in real-world use as in trials, the UK could see: reduced long-term obesity rates fewer diabetes complications lower cardiovascular risk reduced NHS burden over decades The UK typically moves more slowly than the U.S
The Receptor Progression Context Retatrutide is the first investigational triple-hormone receptor agonist to reach late-stage trials
doi: 10.1097/01.mcg.0000159271.43233.45
Chen, Q., Liang, C., Wang, C., & Liu, Z
US$ 25.14
US$ 22.64
US$ 25.21
